Physician profile
Sean Wp Koppe
NPI 1073534681
$151,550.82
in general payments reported to CMS, 2019-2025
6 companies · $35K in 2025
The $35K reported for 2025 was more than what 81% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $7,985 · 2021: $22K · 2022: $18K · 2023: $29K · 2024: $26K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Consulting Fee: $5,640 · Travel and Lodging: $4,210 · Food and Beverage: $2,243 · Honoraria: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,468.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,120.00 |
| Consulting Fee | $5,640.00 |
| Travel and Lodging | $4,210.16 |
| Food and Beverage | $2,242.56 |
| Honoraria | $1,080.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $91,770.40 | 2019-2025 | Vemlidy, Livdelzi |
| Intercept Pharmaceuticals, INC. | $31,285.13 | 2020-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $28,213.79 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $142.30 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $121.13 | 2024 | Imfinzi |
| Abbvie INC. | $18.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Koppe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.